Zoledronic acid

Potent inhibitor of bone resorption (IC50 = 2 nM in mouse calvarial cultures) .1 The mechanism of its action is thought to be via inhibition of osteoclastic activity, induction of osteoclast apoptosis and blockage of osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Clinically useful drug for treatment of osteoporosis2, hypercalcemia of malignancy (HCM), multiple myeloma and bone metastases from solid tumors3. It has also been investigated as an antitumor agent and showing efficacy as an adjuvant therapy in several cancers.4,5